The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting

Dempsey CL, Coop AJ, Shillington A, Farley PA, Eberhardt DR and O’Briant S: Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. Am J Health Syst Pharm. 61:781–786. 2004.PubMed/NCBI

Geling O and Eichler HG: Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications J Clin Oncol. 23:1289–1294. 2005.PubMed/NCBI

Hesketh PJ: Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 18:163–173. 2000. View Article : Google Scholar : PubMed/NCBI

Jordan K, Hinke A, Grothey A, et al: A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 15:1023–1033. 2007. View Article : Google Scholar : PubMed/NCBI

Yonemura M, Katsumata N, Hashimoto H, et al: Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial. Jpn J Clin Oncol. 39:443–448. 2009. View Article : Google Scholar

Rubenstein EB: Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2:284–289. 2004.PubMed/NCBI

Kris MG, Gralla RJ, Clark RA, et al: Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 3:1379–1384. 1985.PubMed/NCBI

National Comprehensive Cancer Network: Antiemesis; V.2. 2009. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdfuri. Accessed April 1, 2009.

National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfuri. Accessed August 9, 2006.

Roila F, Boschetti E, Tonato M, et al: Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol. 14:238–242. 1991. View Article : Google Scholar : PubMed/NCBI

Balu S, Buchner D, Craver C and Gayle J: Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting. Clin Ther. 33:443–455. 2011. View Article : Google Scholar

Ito H, Akuzawa S, Tsutsumi R, et al: Comparative study of the affinities of the 5-HT3 receptor antagonists, YM060, YM114 (KAE-393), granisetron and ondansetron in rat vagus nerve and cerebral cortex. Neuropharmacology. 34:631–637. 1995. View Article : Google Scholar : PubMed/NCBI

Eglen RM, Lee CH, Smith WL, et al: Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol. 114:860–866. 1995. View Article : Google Scholar : PubMed/NCBI

Piraccini G, Stolz R, Tei M, et al: Pharmacokinetic Features of a Novel 5-HT3-Receptor Antagonist: Palonosetron (RS-25259-197). Proc Am Soc Clin Oncol. 20:4002001.

Wong EH, Clark R, Leung E, et al: The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 114:851–859. 1995. View Article : Google Scholar : PubMed/NCBI

Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E and Pegoretti B: Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemo-therapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer. 19:823–832. 2011. View Article : Google Scholar

Campos D, Pereira JR, Reinhardt RR, et al: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 19:1759–1767. 2001.PubMed/NCBI

de Wit R, de Boer AC, vd Linden GH, Stoter G, Sparreboom A and Verweij J: Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 85:1099–1101. 2001.

Gralla RJ, de Wit R, Herrstedt J, et al: Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer. 104:864–868. 2005.

de Wit R, Herrstedt J, Rapoport B, et al: The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer. 40:403–410. 2004.